KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Mikkael A Sekeres, Pau Montesinos, Jan Novak, Jianxiang Wang, Deepa Jeyakumar, Benjamin Tomlinson, Jiri Mayer, Erin Jou, Tadeusz Robak, David C Taussig, Hervé Dombret, Akil Merchant, Naveed Shaik, Thomas O'Brien, Whijae Roh, Xueli Liu, Wendy Ma, Christine G DiRienzo, Geoffrey Chan, Jorge E Cortes

Leukemia 37(10) 2017-2026

PMID37604981
PMCIDPMC10539167
DOI10.1038/s41375-023-02001-z
发表日期2023-08-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。